Rohto Pharmaceutical Co.,Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2022. For the year, the company expected Net Sales were JPY 182,000 million, Operating income was JPY 23,100 million, Profit attributable to owners of parent was JPY 17,100 million, Net income per share was JPY 149.91.